Neptune Wellness Solutions Inc. NEPTF

Healthcare — Drug Manufacturers Specialty & Generic

0.00 0.00 NaN as of 23 Sep

Market cap: $1.6M
P/E: 0.0×

Follow NEPTF

Cash Flow Champion (5y) Revenue Champion (5y)

Growth Flags show if company had growth for consecutive years

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions

in millions of $

	Nov 25			Feb 26			May 26			Aug 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios

Market Cap 1.60

Revenue 39.11

Net Income (78.82)

Free Cash Flow (15.87)

Net Debt 24.73

Current Ratio 0.23

Debt/Equity (0.50)

P/E ratio 0.00

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next 5Y EPS Growth —

in millions of $

Dividends

Payout Ratio 0.00

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2018	Powerpack

predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

	2021	2022	2023	Q'23
Cash	60	9	2	1
Receivables	9	8	8	4
Inventory	17	17	13	10
Other	3	3	1	—
	90	37	24	17

	2021	2022	2023	Q'23
Payables	20	23	27	31
ST’ Debt	0	1	8	26
Other	13	7	6	16
	35	30	41	73

in millions of $

Compound Annual Growth

	10y	5y	3y
Sales	10.93%	19.52%	33.25%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue

	Jun	Sep	Dec	Mar	Year
’26	11	9	8	—	—
’23	16	12	12	12	53
’22	10	13	15	12	49
’21	15	22	3	—	35
’20	3	5	7	7	22
’19	4	5	5	4	19
’18	—	—	—	—	22

in millions of $ · fiscal quarters ending in the months shown

value withheld pending a data check

Operating Cash Flow

	Jun	Sep	Dec	Mar	Year
’26	(5)	1	(3)	—	—
’23	(6)	(8)	(7)	(8)	(29)
’22	(19)	(14)	(10)	(11)	(54)
’21	(7)	(24)	(15)	(10)	(57)
’20	(5)	(7)	(8)	(4)	(24)
’19	(2)	(1)	(1)	(3)	(6)
’18	—	—	—	—	(6)

in millions of $ · fiscal quarters ending in the months shown

Free Cash Flow

	Jun	Sep	Dec	Mar	Year
’26	(5)	1	(3)	—	—
’23	(6)	(8)	(7)	(8)	(29)
’22	(20)	(15)	(11)	(11)	(57)
’21	(8)	(26)	(17)	(12)	(64)
’20	(6)	(10)	(11)	(8)	(34)
’19	(3)	(2)	(3)	(5)	(13)
’18	—	—	—	—	24

in millions of $ · fiscal quarters ending in the months shown

EPS

	Jun	Sep	Dec	Mar	Year
’26	(24.20)	(1.38)	(4.14)	—	—
’23	(28.80)	(157.60)	2.40	(89.20)	(204.80)
’22	(139.86)	(83.92)	(125.87)	(252.40)	(621.60)
’21	(125.87)	(209.79)	(629.37)	(447.55)	(1.45k)
’20	(83.92)	(237.76)	69.93	(433.57)	(713.29)
’19	(55.94)	(41.96)	(55.94)	(167.83)	(307.69)
’18	—	—	—	—	237.76

fiscal quarters ending in the months shown

2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
—	—	1,204.00	980.00	3,178.00	3,444.00	1,344.00	490.00	9.22	0.36	Analyst estimates 2024–2026 Powerpack	Low Price
—	—	2,142.00	3,416.00	7,196.00	9,198.00	5,012.00	5,040.00	785.54	41.60		High Price
—	—	139	—	61	74	165	127	161	50		Employees
—	—	0	0	0	0	0	0	0	1		Revenue/Emp
—	—	17	32	22	19	22	35	49	53		Revenue
—	—	17.94%	24.03%	22.88%	31.15%	(6.22%)	(77.33%)	(15.44%)	(4.70%)		Gross Margin
—	—	(10)	2	6	(18)	(42)	(128)	(84)	(89)		EBT
—	—	(58.06%)	6.61%	27.85%	(94.19%)	(190.22%)	(360.85%)	(173.01%)	(168.78%)		EBT Margin
—	—	(6)	5	7	(18)	(46)	(124)	(84)	(89)		Net Income
—	—	2	3	3	2	6	19	6	3		Depreciation
—	—	0.00	14.59	383.79	327.33	345.83	408.78	404.62	178.18		Revenue/Sh
—	—	(0.08)	1.94	237.76	(307.69)	(713.29)	(1,454.54)	(621.60)	(204.80)		Earnings/Sh
—	—	0.00	1.91	(105.32)	(109.20)	(367.49)	(654.11)	(450.63)	(96.73)		Cash Flow/Sh
—	—	0.00	0.00	527.88	(121.74)	(166.80)	(80.75)	(19.66)	(2.58)		Capex/Sh
—	—	0.00	1.91	422.56	(230.95)	(534.29)	(734.86)	(470.30)	(99.31)		Free CF/Sh
—	—	0.00	21.52	1,201.31	923.84	1,679.34	1,588.28	504.46	(93.33)		Book Value/Sh
—	—	0	2	0	0	0	0	0	0		Shares
—	—	0.00	25.26	70.08	0.00	0.00	0.00	0.00	0.00		PE Ratio
—	—	4.14	2.26	6.27	13.73	4.74	4.49	0.77	0.12		PS Ratio
—	—	1.50	1.47	4.08	4.86	0.98	1.15	0.62	0.00		PB Ratio
—	—	4.90	2.61	6.62	13.48	4.32	3.12	0.83	0.52		EV/Sales
—	—	(9.31)	(28.36)	(71.85)	(19.10)	(2.80)	(1.74)	(0.72)	(0.89)		EV/FCF
—	—	(9)	4	(6)	(6)	(24)	(57)	(54)	(29)		Op' Cash Flow
—	—	(1)	(4)	30	(7)	(11)	(7)	(2)	(1)		Capex
—	—	(9)	4	24	(13)	(34)	(64)	(57)	(29)		FCF
—	—	19	19	21	4	16	55	7	(17)		Working Cap'
—	—	21	18	4	3	3	11	12	23		Total Debt
—	—	11	6	(17)	(5)	(10)	(48)	3	21		Net Debt
—	—	41	48	68	53	108	138	61	(28)		Sh' Equity
—	—	(7.07%)	5.80%	17.04%	(24.26%)	(46.78%)	(78.49%)	(51.37%)	(88.99%)		ROA
—	—	0.00%	0.00%	1.13%	(22.78%)	(73.94%)	(91.71%)	(86.11%)	0.00%		ROIC
—	—	(12.46%)	10.76%	23.70%	(29.43%)	(57.00%)	(100.33%)	(75.58%)	(363.37%)		ROE

predictions in italic, sparklines do not include predictions

All 10 years →

Fiscal years to Mar 2023 · latest quarter Dec 2023

Company	Market cap	P/E	Compare
IMCC IM Cannabis Corp.	$2.0M	0.0×	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	0.0×	Compare
AKAN Akanda Corp.	$2.4M	—	Compare
PTPI Petros Pharmaceuticals, Inc.	$1.0M	0.0×	Compare

Company	Market cap	P/E	Compare
LSDIF Lucy Scientific Discovery Inc.	$900.0K	0.0×	Compare
PRFX PainReform Ltd.	$3.0M	0.0×	Compare
RDHL Redhill Biopharma Ltd.	$3.2M	0.0×	Compare
SBFM Sunshine Biopharma, Inc.	$3.3M	0.0×	Compare

All 86 Drug Manufacturers Specialty & Generic stocks →